News

“The Board of Directors and management team of IRIS International are grateful to Dick Williams for his valuable contributions during a period in which we have experienced very

With the closing, Novartis assumes ownership of certain dry powder and liquid pulmonary formulation and manufacturing assets, including capital equipment and manufacturing facility lease obligations. The sale also

Prasugrel is an investigational antiplatelet agent for the treatment of patients with acute coronary syndromes who are being managed with an artery-opening procedure known as percutaneous coronary intervention,

Impax Laboratories, a technology based specialty pharmaceutical company, applies its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the

Under the licensing agreement, PDL has granted Alexion a license under certain claims in the Queen patent portfolio, and provided Alexion a covenant not to sue in respect

Mr Posner’s career spans over 20 years in global finance positions in the healthcare industry. Most recently, Mr Posner served as executive vice president, and CFO with Pharmacopeia.

Mark Pulido, chairman of the board of Quidel, said: “I speak for the full board of directors of Quidel in recognizing Caren Mason for the outstanding leadership and

In this position, Mr Kurland will be responsible for directing Xoma’s financial strategy, accounting, financial planning and investor relations functions. Prior to joining Xoma, Mr Kurland served as

The patent broadly covers methods of treating obesity with combinations of bupropion and naltrexone, the two active agents in Contrave. It is a companion to the Weber/Cowley composition